Rep. Adriano Espaillat diagnosed with COVID-19 after getting vaccine
More On:
adriano espaillat
NYC will be overrun by rats if de Blasio doesn’t curb trash: pols
Congressman urges state to pull Revel off NY streets after scooter crashes
Andrew Yang ally to challenge Rep. Adriano Espaillat
Burglar takes iPhone, laptops from Bronx pol’s office
New York Rep. Adriano Espaillat has tested positive for COVID-19 — after completing his vaccination against the virus last week.
The congressman, who represents New York’s 13th Congressional district, announced his diagnosis on Twitter Thursday morning.
“I am following guidance from my physician and quarantining at home after having tested positive for COVID-19,” Espaillat, 66, wrote.
He received his first dose of the Pfizer/BioNTech’s vaccine on Dec. 19 and the second sometime last week.
“I received the second dose of the #COVID19vaccine last week and understand the affects take time,” Espaillat continued. “I have continued to be tested regularly, wear my mask and follow the recommended guidelines.”
In a subsequent statement, Espaillat explained that he has been tested regularly — including over the last two days as he traveled from New York to Washington, DC.
His positive results came on Wednesday night. He said he is “feeling well and currently not experiencing any symptoms.”
The Democrat is the latest member of Congress to test positive for the bug after politicians were forced to seek shelter during the insurrection at the Capitol building last week. Some pols said they contracted COVID after being locked in a room with maskless Republicans.
A rep for Espaillat did not answer questions about the congressman’s whereabouts during the siege.
He vowed to continue working remotely until he’s cleared by his doctor.
“I encourage all residents to follow public health guidelines for the safety of our #NY13 community,” he tweeted.
In trials, Pfizer’s vaccine was found to be 82 percent effective at preventing coronavirus about two weeks after the first dose, while one shot of Moderna’s vaccine had 80.2 percent efficacy after about a month, according to Scientific American.
Share this article:
Source: Read Full Article